Precision Medicine Perspectives

This series focuses on targeted treatment approaches for patients with differentiated thyroid cancer.

Expert Danai Dima, MD, reviews results of a retrospective, real-world study of teclistamab in patients with R/R MM who would have been considered ineligible for the MajesTEC-1 trial.

This series comprised of videos and articles focuses on the treatment of patients with newly diagnosed multiple myeloma.

This impactful series of videos and articles explores how real-world data translates to clinical practice in the treatment of patients with metastatic colorectal cancer.

This series comprised of videos and articles explores the evolving treatment landscape for HER2+ early breast cancer.

This series comprised of videos and articles explores recent updates in the management of lower-risk myelodysplastic syndrome.

This series explores the evolving treatment landscape in advanced renal cell carcinoma.

This digital series explores the evolving first-line treatment landscape of advanced or metastatic solid tumors, including non-small cell lung cancer, with an emphasis on the use of immune checkpoint inhibitors alone or in combination with other treatment modalities.

This digital series highlights the mechanistic rationale behind use of tumor-infiltrating lymphocytes in solid tumors, including NSCLC, and addresses the possible challenges and benefits of this treatment approach.

This series explores the development and clinical utility of CAR T-cell therapy in treating patients with mantle cell lymphoma.

This series explores new developments in the molecular pathology and management of NTRK fusion-positive cancers.

This digital series raises awareness regarding the challenges in treating extensive-stage small cell lung cancer through a review of the current treatment landscape, recently approved therapeutics, and emerging options for addressing the consequences of treatment.

This digital series raises awareness regarding the evolving spectrum of precision medicine in advanced prostate cancer through a review of the genomic testing and biomarker landscape as well as the rapidly developing treatment armamentarium, with an emphasis on the potential impact of these newer therapies.

This series highlights the evolving role of BTK inhibitors for the treatment of CLL.